Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05851430 · ClinicalTrials.gov registry record
Galvanize Prospective/Retrospective Pulsed Electric Field Device Registry
A clinical trial of Soft Tissue Lesion, sponsored by Galvanize Therapeutics.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 8
- Study locations
NCT05851430: Recruiting study of Soft Tissue Lesion, sponsored by Galvanize Therapeutics.
NCT05851430 is a study of Soft Tissue Lesion that is actively recruiting participants, run by Galvanize Therapeutics. The registered enrollment target is 1,000 participants. The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05851430, a study of Soft Tissue Lesion, is actively recruiting participants, sponsored by Galvanize Therapeutics.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 8
- Study locations
Study Summary
The goal of this observational registry is to assess the use and performance of Galvanize PEF technology in a real-world setting. The main questions it aims to answer are: * PEF utilization and performance * Monitor safety outcomes and inform future generation devices. Participants will undergo the PEF procedure and be followed per institutional standard of care.
Primary Outcome
Anesthesia type usage
Conditions Studied
Interventions
- DEVICE PEF ablation
Study Locations (8)
Texas
- UT Southwestern Medical Center - Dallas
- University of Texas-Tyler - Tyler
California
- Eisenhower Medical Center - Rancho Mirage
Florida
- NCH Baker - Naples
New York
- New York Presbyterian Langone Health - New York
North Carolina
- Duke University Hospital - Durham
Pennsylvania
- Lankenau Institute for Medical Research (LIMR) - Wynnewood
South Carolina
- AnMed Health - Anderson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-06-23 |
| Est. Completion | 2028-12-31 |
What NCT05851430 shows while recruiting
NCT05851430 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Soft Tissue Lesion appearing as the primary indexed condition, and to 1 intervention - of which PEF ablation is the first listed.
NCT05851430 lists 8 locations in 7 states (Texas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT05851430 about?
NCT05851430 is a clinical study titled "Galvanize Prospective/Retrospective Pulsed Electric Field Device Registry". The goal of this observational registry is to assess the use and performance of Galvanize PEF technology in a real-world setting. The main questions it aims to answer are: * PEF utilization and performance * Monitor safety outcomes and inform future generation devices. Participants will undergo th...
What is the current status of trial NCT05851430?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-06-23. Estimated completion is 2028-12-31.
What conditions does trial NCT05851430 study?
This clinical trial studies the following conditions: Soft Tissue Lesion.
What interventions are being tested in trial NCT05851430?
The interventions under investigation include: PEF ablation (DEVICE).
Who is sponsoring clinical trial NCT05851430?
This trial is sponsored by Galvanize Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05851430 being conducted?
This trial has 8 study locations across California, Florida, New York, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Lesion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI